NO2023040I1 - Atogepant or a pharmaceutically acceptable salt thereof - Google Patents

Atogepant or a pharmaceutically acceptable salt thereof

Info

Publication number: NO2023040I1
Authority: NO; Norway
Prior art keywords: atogepant; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2010-11-12

Application number

NO2023040C

Other languages

English (en)

Original Assignee

Merck Sharp & Dohme Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-12

Filing date

2023-10-20

Publication date

2023-10-20

2023-10-20 Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc

2023-10-20 Publication of NO2023040I1 publication Critical patent/NO2023040I1/no

Links

QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 title 1
229940070146 atogepant Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems

NO2023040C 2010-11-12 2023-10-20 Atogepant or a pharmaceutically acceptable salt thereof NO2023040I1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US41307710P	2010-11-12	2010-11-12
US201061425034P	2010-12-20	2010-12-20
PCT/US2011/060081 WO2012064910A1 (en)	2010-11-12	2011-11-10	Piperidinone carboxamide azaindane cgrp receptor antagonists

Publications (1)

Publication Number	Publication Date
NO2023040I1 true NO2023040I1 (no)	2023-10-20

Family

ID=45034191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO2023040C NO2023040I1 (no)	2010-11-12	2023-10-20	Atogepant or a pharmaceutically acceptable salt thereof

Country Status (42)

Country	Link
US (8)	US8481556B2 (no)
EP (2)	EP2821407B1 (no)
JP (1)	JP5642883B2 (no)
KR (1)	KR101537877B1 (no)
CN (1)	CN103328478B (no)
AR (1)	AR083831A1 (no)
AU (1)	AU2011326454B2 (no)
BR (1)	BR112013011448B8 (no)
CA (1)	CA2817100C (no)
CL (1)	CL2013001289A1 (no)
CO (1)	CO6801723A2 (no)
CR (1)	CR20130214A (no)
CY (1)	CY1118362T1 (no)
DK (2)	DK2638042T3 (no)
DO (1)	DOP2013000103A (no)
EA (1)	EA022850B1 (no)
EC (1)	ECSP13012676A (no)
ES (2)	ES2604827T3 (no)
FI (1)	FIC20230034I1 (no)
FR (1)	FR23C1039I1 (no)
GT (1)	GT201300122A (no)
HK (1)	HK1200163A1 (no)
HR (2)	HRP20141108T1 (no)
HU (2)	HUE031010T2 (no)
IL (1)	IL225978A (no)
LT (1)	LT2821407T (no)
MA (1)	MA34650B1 (no)
ME (2)	ME02552B (no)
MX (1)	MX2013005246A (no)
MY (1)	MY165113A (no)
NI (1)	NI201300043A (no)
NL (1)	NL301248I2 (no)
NO (1)	NO2023040I1 (no)
NZ (1)	NZ610468A (no)
PE (1)	PE20140240A1 (no)
PL (2)	PL2821407T3 (no)
PT (2)	PT2638042E (no)
RS (2)	RS53610B1 (no)
SG (2)	SG190137A1 (no)
SI (2)	SI2638042T1 (no)
TW (3)	TWI522355B (no)
WO (1)	WO2012064910A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI522355B (zh) *	2010-11-12	2016-02-21	默沙東藥廠	六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
EP2685826B1 (en)	2011-03-18	2016-02-03	Merck Sharp & Dohme Corp.	Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9487523B2 (en) *	2012-03-14	2016-11-08	Merck Sharp & Dohme Corp.	Process for making CGRP receptor antagonists
US9174989B2 (en) *	2012-05-09	2015-11-03	Merck Sharp & Dohme Corp.	Process for making CGRP receptor antagonists
KR20210153745A (ko) *	2013-09-16	2021-12-17	머크 샤프 앤드 돔 코포레이션	Cgrp 수용체 길항제를 위한 제제
EP3102564A4 (en) *	2014-02-05	2017-10-18	Merck Sharp & Dohme Corp.	Tablet formulation for cgrp-active compounds
FR3030521B1 (fr) *	2014-12-23	2019-07-26	Galderma Research & Development	Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
GB201707938D0 (en)	2017-05-17	2017-06-28	Univ Sheffield	Compounds
GB201908430D0 (en) *	2019-06-12	2019-07-24	Heptares Therapeutics Ltd	Cgrp antagonist compounds
CN110787163B (zh) *	2019-12-05	2020-06-02	河北医科大学第二医院	一种用于神经保护和促进神经再生的药物组合物及其制剂
CN112353767A (zh) *	2020-11-16	2021-02-12	海南锦瑞制药有限公司	一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
CA3206184A1 (en)	2020-12-22	2022-06-30	Allergan Pharmaceuticals International Limited	Treatment of migraine
EP4301362A1 (en)	2021-03-02	2024-01-10	CGRP Diagnostics GmbH	Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
WO2023119327A1 (en) *	2021-12-20	2023-06-29	Msn Laboratories Private Limited, R&D Center	Process for the preparation of a pure amorphous form of ubrogepant
TW202342028A (zh) *	2022-04-29	2023-11-01	大陸商熙源安健醫藥（上海）有限公司	哌啶甲醯胺氮雜茚滿類衍生物及其製備方法和用途
WO2024081718A1 (en)	2022-10-11	2024-04-18	Allergan Pharmaceuticals International Limited	Cgrp receptor antagonist for the treatment of migraine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
WO2004087649A2 (en)	2003-03-14	2004-10-14	Merck & Co., Inc.	Benodiazepine spirohydantoin cgrp receptor antagonists
JP4690313B2 (ja)	2003-03-14	2011-06-01	メルク・シャープ・エンド・ドーム・コーポレイション	カルボキサミドスピロヒダントインｃｇｒｐ受容体アンタゴニスト
JO2355B1 (en) *	2003-04-15	2006-12-12	ميرك شارب اند دوم كوربوريشن	Hereditary calcitonin polypeptide receptor antagonists
EP1797073B1 (en) *	2004-09-13	2010-04-14	Merck Sharp & Dohme Corp.	Bicyclic anilide spirolactam cgrp receptor antagonists
US7390798B2 (en)	2004-09-13	2008-06-24	Merck & Co., Inc.	Carboxamide spirolactam CGRP receptor antagonists
CA2599925A1 (en) *	2005-03-14	2006-09-21	Merck & Co., Inc.	Cgrp receptor antagonists
BRPI0711352A2 (pt)	2006-05-09	2011-09-27	Merck & Co Inc	composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular
WO2008153849A1 (en) *	2007-06-05	2008-12-18	Merck & Co., Inc.	Carboxamide heterocyclic cgrp receptor antagonists
EP2225237A2 (de) *	2007-11-22	2010-09-08	Boehringer Ingelheim International GmbH	Organische verbindungen
US8044043B2 (en) *	2008-04-11	2011-10-25	Bristol-Myers Squibb Company	CGRP receptor antagonists
US8765763B2 (en) *	2009-06-05	2014-07-01	Boehringer Ingelheim International Gmbh	Substituted piperazines as CGRP antagonists
TWI522355B (zh) *	2010-11-12	2016-02-21	默沙東藥廠	六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
AU2011326455A1 (en) *	2010-11-12	2013-05-23	Merck Sharp & Dohme Corp.	Piperidinone carboxamide indane CGRP receptor antagonists
EP2654423B1 (en) *	2010-12-22	2016-12-07	Merck Sharp & Dohme Corp.	Fused heterocyclic azaindane carboxamide cgrp receptor antagonists
US8895572B2 (en) *	2010-12-22	2014-11-25	Merck Sharp & Dohme Corp.	Fused heterocyclic indane carboxamide CGRP receptor antagonists
EP2685826B1 (en) *	2011-03-18	2016-02-03	Merck Sharp & Dohme Corp.	Piperidinone carboxamide spirohydantoin cgrp receptor antagonists
US9109209B2 (en) *	2011-09-08	2015-08-18	Codexis, Inc.	Biocatalysts and methods for the synthesis of substituted lactams
US9487523B2 (en) *	2012-03-14	2016-11-08	Merck Sharp & Dohme Corp.	Process for making CGRP receptor antagonists
KR102061180B1 (ko) *	2012-03-14	2019-12-31	머크 샤프 앤드 돔 코포레이션	비대칭 상 이동 촉매로서의 비스-4급 신코나 알칼로이드 염
US9227973B2 (en) *	2012-05-09	2016-01-05	Merck Sharp & Dohme Corp.	Pyridine CGRP receptor antagonists
US9227972B2 (en) *	2012-05-09	2016-01-05	Merck Sharp & Dohme Corp.	Aliphatic spirolactam CGRP receptor antagonists
WO2013169567A1 (en) *	2012-05-09	2013-11-14	Merck Sharp & Dohme Corp.	Spirolactam cgrp receptor antagonists
US9174989B2 (en) *	2012-05-09	2015-11-03	Merck Sharp & Dohme Corp.	Process for making CGRP receptor antagonists
KR20210153745A (ko) *	2013-09-16	2021-12-17	머크 샤프 앤드 돔 코포레이션	Cgrp 수용체 길항제를 위한 제제
EP3102564A4 (en) *	2014-02-05	2017-10-18	Merck Sharp & Dohme Corp.	Tablet formulation for cgrp-active compounds
CN106456662A (zh) *	2014-02-24	2017-02-22	奥利金制药公司	口服给药的戊聚糖多硫酸盐的组合物及其使用方法
US20180092899A1 (en) *	2016-09-30	2018-04-05	Merck Sharp & Dohme Corp.	Method of treating acute migraine with cgrp-active compound

2011
- 2011-11-09 TW TW104104475A patent/TWI522355B/zh active
- 2011-11-09 TW TW104104474A patent/TWI501968B/zh active
- 2011-11-09 TW TW100140962A patent/TWI487706B/zh active
- 2011-11-10 PL PL14185954T patent/PL2821407T3/pl unknown
- 2011-11-10 DK DK11787987.4T patent/DK2638042T3/en active
- 2011-11-10 EP EP14185954.6A patent/EP2821407B1/en active Active
- 2011-11-10 EP EP11787987.4A patent/EP2638042B1/en active Active
- 2011-11-10 ES ES14185954.6T patent/ES2604827T3/es active Active
- 2011-11-10 PL PL11787987T patent/PL2638042T3/pl unknown
- 2011-11-10 KR KR1020137014960A patent/KR101537877B1/ko active IP Right Grant
- 2011-11-10 BR BR112013011448A patent/BR112013011448B8/pt active IP Right Grant
- 2011-11-10 RS RS20140621A patent/RS53610B1/en unknown
- 2011-11-10 ME MEP-2016-257A patent/ME02552B/me unknown
- 2011-11-10 DK DK14185954.6T patent/DK2821407T3/da active
- 2011-11-10 MY MYPI2013001607A patent/MY165113A/en unknown
- 2011-11-10 SI SI201130327T patent/SI2638042T1/sl unknown
- 2011-11-10 WO PCT/US2011/060081 patent/WO2012064910A1/en active Application Filing
- 2011-11-10 ES ES11787987.4T patent/ES2525021T3/es active Active
- 2011-11-10 LT LTEP14185954.6T patent/LT2821407T/lt unknown
- 2011-11-10 ME MEP-2014-145A patent/ME01922B/me unknown
- 2011-11-10 PT PT117879874T patent/PT2638042E/pt unknown
- 2011-11-10 SG SG2013034145A patent/SG190137A1/en unknown
- 2011-11-10 AU AU2011326454A patent/AU2011326454B2/en active Active
- 2011-11-10 US US13/293,186 patent/US8481556B2/en active Active
- 2011-11-10 PT PT141859546T patent/PT2821407T/pt unknown
- 2011-11-10 CA CA2817100A patent/CA2817100C/en active Active
- 2011-11-10 HU HUE14185954A patent/HUE031010T2/en unknown
- 2011-11-10 MX MX2013005246A patent/MX2013005246A/es active IP Right Grant
- 2011-11-10 EA EA201390683A patent/EA022850B1/ru not_active IP Right Cessation
- 2011-11-10 CN CN201180064736.XA patent/CN103328478B/zh active Active
- 2011-11-10 NZ NZ610468A patent/NZ610468A/en unknown
- 2011-11-10 SG SG10201509335VA patent/SG10201509335VA/en unknown
- 2011-11-10 JP JP2013538871A patent/JP5642883B2/ja active Active
- 2011-11-10 US US13/293,166 patent/US8754096B2/en active Active
- 2011-11-10 PE PE2013000966A patent/PE20140240A1/es active IP Right Grant
- 2011-11-10 AR ARP110104204A patent/AR083831A1/es active IP Right Grant
- 2011-11-10 RS RS20160964A patent/RS55416B1/sr unknown
- 2011-11-10 SI SI201131014A patent/SI2821407T1/sl unknown
- 2011-11-10 US US13/293,177 patent/US8912210B2/en active Active
2013
- 2013-04-25 IL IL225978A patent/IL225978A/en active IP Right Grant
- 2013-05-06 MA MA35880A patent/MA34650B1/fr unknown
- 2013-05-09 DO DO2013000103A patent/DOP2013000103A/es unknown
- 2013-05-09 CL CL2013001289A patent/CL2013001289A1/es unknown
- 2013-05-10 CR CR20130214A patent/CR20130214A/es unknown
- 2013-05-10 NI NI201300043A patent/NI201300043A/es unknown
- 2013-05-10 GT GT201300122A patent/GT201300122A/es unknown
- 2013-05-30 CO CO13133033A patent/CO6801723A2/es active IP Right Grant
- 2013-06-12 EC ECSP13012676 patent/ECSP13012676A/es unknown
2014
- 2014-09-12 US US14/485,259 patent/US9499545B2/en active Active
- 2014-11-14 HR HRP20141108AT patent/HRP20141108T1/hr unknown
2015
- 2015-01-15 HK HK15100502.4A patent/HK1200163A1/zh unknown
2016
- 2016-10-14 US US15/293,569 patent/US9833448B2/en active Active
- 2016-12-05 HR HRP20161641TT patent/HRP20161641T1/hr unknown
- 2016-12-06 CY CY20161101255T patent/CY1118362T1/el unknown
2017
- 2017-12-04 US US15/830,131 patent/US10272077B2/en active Active
2019
- 2019-04-26 US US16/396,056 patent/US20190275024A1/en not_active Abandoned
2020
- 2020-07-28 US US16/940,943 patent/US20210008055A1/en not_active Abandoned
2023
- 2023-10-20 NO NO2023040C patent/NO2023040I1/no unknown
- 2023-10-25 HU HUS2300037C patent/HUS2300037I1/hu unknown
- 2023-10-31 NL NL301248C patent/NL301248I2/nl unknown
- 2023-10-31 FR FR23C1039C patent/FR23C1039I1/fr active Active
- 2023-11-10 FI FIC20230034C patent/FIC20230034I1/fi unknown

Also Published As

Publication number	Publication date
KR20130087037A (ko)	2013-08-05
HRP20161641T1 (hr)	2017-01-13
ME02552B (me)	2017-02-20
PL2638042T3 (pl)	2015-03-31
CY1118362T1 (el)	2017-06-28
DK2821407T3 (da)	2017-01-02
EP2821407A1 (en)	2015-01-07
EP2638042B1 (en)	2014-09-24
LT2821407T (lt)	2016-12-12
US20150005330A1 (en)	2015-01-01
FIC20230034I1 (fi)	2023-11-10
NI201300043A (es)	2013-07-01
EA201390683A1 (ru)	2013-09-30
DK2638042T3 (en)	2015-01-05
US20120122899A1 (en)	2012-05-17
EP2638042A1 (en)	2013-09-18
SI2638042T1 (sl)	2015-01-30
TWI501968B (zh)	2015-10-01
CN103328478A (zh)	2013-09-25
US10272077B2 (en)	2019-04-30
CO6801723A2 (es)	2013-11-29
US20210008055A1 (en)	2021-01-14
ME01922B (me)	2015-05-20
AR083831A1 (es)	2013-03-27
RS55416B1 (sr)	2017-04-28
NZ610468A (en)	2015-06-26
US20120122911A1 (en)	2012-05-17
MY165113A (en)	2018-02-28
BR112013011448B8 (pt)	2022-03-29
PT2638042E (pt)	2014-12-09
US8912210B2 (en)	2014-12-16
CL2013001289A1 (es)	2013-08-09
AU2011326454A1 (en)	2013-05-23
TW201305165A (zh)	2013-02-01
SG190137A1 (en)	2013-07-31
ES2604827T3 (es)	2017-03-09
BR112013011448A2 (pt)	2016-08-09
US9499545B2 (en)	2016-11-22
NL301248I2 (nl)	2023-11-20
IL225978A0 (en)	2013-06-27
TWI522355B (zh)	2016-02-21
TWI487706B (zh)	2015-06-11
PT2821407T (pt)	2016-12-06
EA022850B1 (ru)	2016-03-31
KR101537877B1 (ko)	2015-07-17
DOP2013000103A (es)	2013-10-15
US20120122900A1 (en)	2012-05-17
MX2013005246A (es)	2013-05-28
CN103328478B (zh)	2015-10-07
JP2013542260A (ja)	2013-11-21
US9833448B2 (en)	2017-12-05
MA34650B1 (fr)	2013-11-02
TW201520214A (zh)	2015-06-01
PE20140240A1 (es)	2014-03-14
WO2012064910A1 (en)	2012-05-18
SI2821407T1 (sl)	2016-12-30
TW201520213A (zh)	2015-06-01
EP2821407B1 (en)	2016-09-21
CA2817100C (en)	2015-09-29
US8754096B2 (en)	2014-06-17
US20180092900A1 (en)	2018-04-05
CR20130214A (es)	2013-06-28
ECSP13012676A (es)	2013-08-30
AU2011326454B2 (en)	2015-05-21
JP5642883B2 (ja)	2014-12-17
HK1200163A1 (zh)	2015-07-31
US20170027925A1 (en)	2017-02-02
HUS2300037I1 (hu)	2023-11-28
HRP20141108T1 (hr)	2015-01-16
PL2821407T3 (pl)	2017-04-28
IL225978A (en)	2015-11-30
ES2525021T3 (es)	2014-12-16
CA2817100A1 (en)	2012-05-18
GT201300122A (es)	2015-06-02
US8481556B2 (en)	2013-07-09
FR23C1039I1 (fr)	2023-12-08
SG10201509335VA (en)	2015-12-30
RS53610B1 (en)	2015-04-30
BR112013011448B1 (pt)	2021-06-01
US20190275024A1 (en)	2019-09-12
HUE031010T2 (en)	2017-06-28

Publication	Publication Date	Title
NO2021039I1 (no)	2021-09-16	pibrentasvir or a pharmaceutically acceptable salt thereof - forlenget SPC
NO2020006I1 (no)	2020-03-11	upadacitinib or a pharmaceutically acceptable salt thereof
NO2023040I1 (no)	2023-10-20	Atogepant or a pharmaceutically acceptable salt thereof
NO2021034I1 (no)	2021-09-09	pemigatinib or a pharmaceutically acceptable salt thereof
NO2022033I1 (no)	2022-07-22	Rimegepant or a pharmaceutically acceptable salt thereof
NL301157I2 (nl)	2023-11-09	odevixibat of een farmaceutisch aanvaardbaar zout daarvan
NO2022031I1 (no)	2022-07-20	Voxelotor or a tautomer or pharmaceutically acceptable salt thereof
NO2021040I1 (no)	2021-09-16	glecaprevir or a pharmaceutically acceptable salt or ester thereof- forlenget SPC
NO2021033I1 (no)	2021-09-06	Selineksor eller et farmasøytisk akseptabelt salt derav
NO2021041I1 (no)	2021-09-20	remimazolam or a pharmaceutically acceptable salt thereof
FIC20230028I1 (fi)	2023-08-28	Deukravasitinibi tai sen framaseuttisesti hyväksyttävä suola
NO2022010I1 (no)	2022-04-07	ripretinib, or a pharmaceutically acceptable salt thereof
NL301084I2 (nl)	2021-01-28	remdesivir of een farmaceutisch aanvaardbaar zout of ester daarvan
FIC20240012I1 (fi)	2024-04-18	Omaveloksoloni tai sen farmaseuttisesti hyväksyttävä suola
FIC20230019I1 (fi)	2023-05-24	Maraliksibaatti tai sen farmaseuttisesti hyväksyttävä suola, erityisesti maraliksibaattikloridi
NO2021013I1 (no)	2021-03-23	filgotinib or a salt thereof
NO2020018I1 (no)	2020-06-17	Darolutamide, optionally in the form of a pharmaceutically acceptable salt or ester thereof
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NO2020037I1 (no)	2020-11-16	alpelisib eller et farmasøytisk akseptabelt salt derav
NO2019024I1 (no)	2019-05-20	Brigatinib eller et farmasøytisk akseptabelt salt derav
NO2019019I1 (no)	2019-04-24	Doravirin eller et farmasøytisk akseptabelt salt derav
NO2017059I1 (no)	2017-11-13	ribosiklib eller et farmasøytisk akseptabelt salt derav
NO2015012I2 (no)	2015-04-22	Ombitasvir, eller et farmasøytisk akseptabelt salt derav
NO2023002I1 (no)	2023-01-05	Lasmiditan or a pharmaceutically acceptable salt thereof
BR112012024815A2 (pt)	2017-04-11	imunoderivados fungicidas